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Much of our present understanding of the action of prosta- 
glandins derives from observing the effects of nonsteroidal 
anti-inflammatory drugs (NSAIDs). The anti-inflammatory, 
antipyretic, and analgesic effects resulting from inhibition 
of prostaglandin synthesis by aspirin, ibuprofen, and other 
NSAlDs indicate that these lipid-signaling molecules are 
critical regulators of immune responses, fever, and pain; 
we now know that prostaglandins are also ubiquitous auto- 
crinelparacrine modulators of cellular responses and likely 
play roles in mitogenesis and apoptosis. (For a general 
review, see Smith and Dewitt, 1995). It therefore seems 
fitting that our latest advance in the understanding of the 
physiological roles of prostaglandins should again result 
from inhibition of prostaglandin synthesis, this time as a 
result of the genetic ablation of the enzymes required for 
their synthesis. In this issue of Cell, Langenbach et al. 
(1995) and Morham et al. (1995) describe the construction 
and phenotypic characterization of transgenic mice defi- 
cient in two isozymes central to prostaglandin synthesis, 
cyclooxygenases 1 and 2 (COX-1 and COX-2), also known 
as prostaglandin H synthase 1 and 2 (PGHS-1 and PGHSQ). 
The uniquely different phenotypes of the two knockout 
strains confirm that the closely related COX-1 and COX-2 
isozymes are not redundant, and the genetic pathologies 
of these mice, or lack thereof, allow us more precisely to 
assign specific signaling roles to the two prostaglandin 
biosynthetic pathways defined by these enzymes. In a re- 
lated article, Tsujii and DuBois (1995 [this issue of Cc//J) 
describe an unexpected function for the COX-2 pathway 
and, at the same time, provide a potential solution to a 
vitally important mystery: how does aspirin reduce the inci- 
dence of colon cancer? 
Separate Prostoglandin Biosynthetic Pathways 
COX catalyzes the first committed step in the formation of 
prostaglandins and thromboxanes (Figure 1). Arachidonic 
acid (AA) released from membrane phospholipids by phos- 
pholipase A2 is converted to prostaglandin HP (PGH*) 
through the action of COX; PGH2 is then converted to 
PGDz, PGE,, PGF*, PGlz, or thromboxane AZ by cell- 
specific synthases. Prostaglandins act, at least in part, 
through specific G protein-linked receptors to modulate 
the levels of the second messengers CAMP and Ca*+. 
There are two COX enzymes, referred to as COX-1 and 
COX-2. The relatively recent and unexpected discovery 
of the second of these isozymes has stimulated a great 
deal of research in the field, much of which has been di- 
rected at determining the biological rationale for this ap- 
parent redundancy. COX-1 and COX-2 are encoded by 
separate genes, but the enzymes are structurally homolo- 
gous, and both catalyze the formation of PGH2 from AA 
with similar kinetic properties. 
Minireview 
COX-1 is a constitutive enzyme whose expression ap- 
pears to be regulated only developmentally; this enzyme 
produces prostaglandins in the endoplasmic reticulum, 
which exit cells and signal through cell surface G protein- 
linked receptors. Prostaglandins produced by constitutive 
COX-1 are thought to mediate physiological responses to 
circulating hormones that require constant or rapid modu- 
lation (or both), the so-called housekeeping functions. 
These events include the regulation of renal HP0 and Na+ 
reabsorption, gastroprotection in the stomach, and vascu- 
lar homeostasis. As might be expected, COX-1 is ex- 
pressed at higher concentrations in tissues and in cells 
where prostaglandins have specialized signaling func- 
tions, such as kidney, stomach, platelets, and vascular 
endothelium. 
In contrast with COX-1, COX-2 is an inducible enzyme 
that is normally absent from cells, but that is expressed in 
response to growth factors, tumor promoters, or cytokines. 
(COX-2 is expressed in a few specialized tissues in the 
apparent absence of activation, such as brain, testes, and 
macula densa of kidney). In fibroblasts, the gene encoding 
COX-2 behaves as an immediate-early gene and is rapidly 
but transiently expressed in response to mitogens. The 
most obvious rationale for a second inducible COX-2- 
that it is induced to augment constitutive prostaglandin 
synthesis by COX-1 -no longer seems tenable. First, in- 
duction of COX-2 often results in only nominal increases 
in cellular PGH, biosynthetic activity (Smith and DeWitt, 
Figure 1. Pathway of Prostaglandin Biosynthesis by COX-1 and COX-2 
TXA*, thromboxane AZ. 
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1995). Second, it appears that the two enzymes utilize 
different phospholipase systems, lipid stores of AA, or both 
(Murakami et al., 1994; Reddy and Herschman, 1994). In 
addition, COX-2 produces prostaglandins within or on the 
nuclear envelope, while COX-1 forms products on the en- 
doplasmic reticulum (Morita et al., 1995). One possibility 
is that prostaglandins produced in the nucleus may affect 
gene transcription or other nuclear events, although a 
mechanism for such action is not known. Most likely, 
COX-1 and COX-2 are enzymes of separate prostaglandin 
synthetic pathways. The COX-1 pathway, because of its 
generalized constitutive expression, is part of an acute 
signaling system. In contrast, the COX-2 pathway, be- 
cause of the time lag required for induction, produces pros- 
taglandins that likely are only employed in the secondary 
elaboration of physiological events such as inflammation, 
mitogenesis, and ovulation. The observation that COX-2 
is an immediate-early gene that produces prostaglandins 
within or on the nuclear membrane suggested that this 
enzyme may be involved in replication, differentiation, or 
both. Therefore, when aspirin was found to reduce mortal- 
ity resulting from cancers of the colon, this enzyme seemed 
the most likely target, a hypothesis that has been strength- 
ened by observations of increased COX-2 expression in 
colonic carcinomas and, most recently, by the study pre- 
sented by Tsujii and DuBois (1995) demonstrating a possi- 
ble role for COX-2 in the progression of these cancers. 
One aspect of COX-2 function that is more clearly de- 
fined is its role in inflammation. Absent from normal tissue, 
COX-2 is expressed at sites of inflammation and in mono- 
cytes and macrophages stimulated with lipopolysaccha- 
ride or interleukin-1 (IL-l). Importantly, expression of 
COX-2 is inhibited by anti-inflammatory glucocorticoids, 
both in vivo and in vitro, and by anti-inflammatory cyto- 
kines such as IL-4 and IL-lo. The implication that inflam- 
mation may be mediated primarily through prostaglandins 
produced by COX-2 has been well appreciated by pharma- 
ceutical companies. Two major side effects of long-term 
use of anti-inflammatory doses of NSAlDs are stomach 
ulceration and nephrotoxicity. Since COX-1 is the major 
source of prostaglandins in stomach and kidney, it seemed 
likely that NSAlDs that inhibit only COX-2 would have re- 
duced gastric and renal toxicity and possibly better anti- 
inflammatory properties. Such compounds have already 
been developed, and tests with these drugs have largely 
confirmed this hypothesis. Selective inhibitors of COX-2 
are effective anti-inflammatory, antipyretic, and analgesic 
agents that cause low or negligible levels of gastric irrita- 
tion, at least in animal models (Chan et al., 1994; Masferrer 
et al., 1994; Seibert et al., 1994). 
COX-1 Knockout Mice 
Overall, the most surprising finding by Langenbach et al. 
(1995) is that mice lacking COX-1 have so few phenotypic 
abnormalities. One might predict that loss of an enzyme 
that is expressed at some level in almost every tissue and 
that produces prostaglandins thought to be critical regula- 
tors of physiological events, for example, kidney and stom- 
ach function, would at least be debilitating. In fact, the 
only serious deficiency found in these mice was a failure 
to produce viable offspring when homozygote (Pfgsl-‘-) 
mice were cross-bred. Heterozygotes (PtgsF) of either 
sex, when mated with homozygotes (PtgsI-‘-), produced 
offspring, indicating that COX-1 expression in as few as 
50% of the pups was sufficient for the health of the entire 
litter. Prostaglandins are known to be involved in ovulation, 
spermatogenesis, and parturition. The breeding studies 
rule out the need for COX-1 during ovulation and sperma- 
togenesis or for male fertility and indicate an essential 
requirement for COX-I during parturition. 
As would be predicted, platelets from mice deficient in 
COX-1 are unresponsive to aggregation induced by addi- 
tion of AA. These results confirm that COX-1 alone is ex- 
pressed in platelets. Since these cells have no nuclei, they 
cannot compensate by expressing COX-2. Inhibition of 
platelet COX-1, which reduces thromboxane AZ produc- 
tion, is the basis of the prophylactic effects of aspirin on 
cardiovascular disease. One would predict that these mice 
may be refractory to development of heart disease. 
The most unexpected finding from COX-l-deficient 
mice is their lack of spontaneous stomach ulceration since 
there is strong experimental evidence for the role of prosta- 
glandins formed via COX-1 in maintaining stomach func- 
tion. All NSAlDs that inhibit COX-1 can produce gastric 
ulcerations, whereas newer NSAIDs, which only inhibit 
COX-2, do not. NSAlDs are a chemically diverse group 
of compounds, reducing thechances that ulceration is due 
to an action of NSAlDs secondary to COX inhibition. Also, 
ulceration resulting from ingestion of NSAlDs can also be 
eliminated by the concurrent ingestion of PGE analogs. 
Nevertheless, mice lacking COX-1 do not develop ulcers, 
although these animals seem slightly less sensitive than 
wild-type mice to ulceration induced by the NSAID indo- 
methacin. A compensatory production of stomach prosta- 
glandins via COX-2 has been ruled out as an explanation 
for the lack of stomach ulceration in PtgsF mice, so at 
this stage there is no ready explanation for these surpris- 
ing findings. However, it should be noted that NSAlDs 
inhibit the cyclooxygenase activity of the COX isoforms 
and leave the peroxidase activities of these enzymes unal- 
tered, while the Ptgsl-I- mice are deficient in both of these 
enzymatic activities. It is possible that ulceration is due 
to peroxidation products of COX-1. 
A second unanticipated finding in COX-l-deficient mice 
is the reduced responsiveness of these mice to AA in the 
ear swelling assay, a measure of acute inflammation. As 
mentioned previously, the present model attributesforma- 
tion of inflammatory prostaglandins to COX-2, and recent 
findings demonstrating that COX-2-selective inhibitors 
have excellent anti-inflammatory properties support this 
view. Inflammation involves an early response phase (less 
than 2 hr) during which inflammatory cells are recruited 
and initial edema formation occurs. Apparently, prosta- 
glandins produced by COX-1 play an essential role in these 
early events. The AA ear inflammation assays performed 
by Langenbach et al. (1995) were scored at 2 hr. At later 
times, as monocytes are recruited and cytokine production 
increased, COX-2 is induced, and prostaglandins pro- 
duced by this isozyme are likely to predominate in the 
inflammatory reaction. The results of the ear inflammation 
assays make sense in that COX-1 is the only enzyme pres- 
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ent when the inflammatory response begins, and signifi- 
cant induction of COX-2 does not occur at sites of inflam- 
mation until after 2 hr (Seibert et al., 1994). One might 
predict that mice deficient in COX-2 would have a normal 
response to the same 2 hr AA ear-swelling assay, which 
is exactly what was found. 
COX-2 Knockout Mice 
Unlike healthy COX-l-deficient (Ptgsl-I-) mice, homozy- 
gous mice deficient in COX-2 (Pfgs2-I-) begin to die around 
8 weeks of age, and few survive as long as 16 weeks. 
All tissues examined were normal in these mice except 
kidney. Nephropathy is observable by 6 weeks and in- 
creases in severity until death. Examination of Ptgs2-‘- 
mice suggests that kidney maturation ceases prematurely 
after only a small percentage of nephrons develop and 
that thevast majority of glomeruli and tubules remain small 
and immature. As the animals grow older, the overworked 
functional nephrons begin to atrophy, and glomerular scle- 
rosis, interstitial inflammation, and fibrosis increase, ulti- 
mately leading to kidney failure. 
The pattern of COX-2 expression in kidney is distinctly 
different from that of COX-1 expression, indicating that 
the two prostaglandin pathways have unique functions in 
the kidney, a view reinforced by the healthy phenotype 
of the COX-l-deficient mice. COX-2 is expressed in the 
macula densa of the juxtaglomerular apparatus of rat kid- 
ney (Harris et al., 1994), cells that sense blood NaCl con- 
centrations and modulate release of renin, an important 
regulator of NaCI, volume, and blood pressure homeosta- 
sis. COX-1 is most prevalent in collecting tubule, and pros- 
taglandins produced by this enzyme regulatevasopressin- 
stimulated HZ0 and Na+ reabsorption, a function either 
that is not vital or that can be compensated for by other 
mechanisms. One explanation for renal pathologies suf- 
fered by the ftgs2-‘- mice, offered by Morham et al. (1995), 
is that COX-2 is required for vascular perfusion during 
renal development, and in its absence only a small number 
of nephrons mature fully. Alternatively, COX-2 may pro- 
duce prostaglandins involved in the production of growth 
factors required for renal development. 
One finding, unexpected by Morham et al. (1995), was 
that Ptgs2-‘- mice and Ptgs2+‘+ mice both responded simi- 
larly to AA in the ear swelling assay of inflammation. As 
discussed above, COX-2 is not significantly expressed at 
sites of inflammation until after 2 hr (Seibert et al., 1994), 
the time at which these assays were scored. Therefore, 
the lack of an effect of COX-2 loss on this response is 
understandable. It will be interesting to test these animals 
in inflammation assays of longer duration and especially in 
the presence of glucocorticoids to find out how dependent 
inflammatory responses are on prostaglandins produced 
by COX-2 and how much of the anti-inflammatoryeffectsof 
glucocorticoids are mediated through inhibition of COX-2 
expression. Morham et al. (1995) did measure one model 
of inflammation with a longer time course. Experiments 
conducted with tetradecanoyl phorbol acetate (TPA) and 
scored at 6 hr revealed no diminution of ear swelling in 
Ptgs2-I- compared with wild-type mice. However, we would 
interpret these experiments cautiously. While TPA is a 
known inducer of COX-2, and this enzyme might pre- 
viously have been presumed to be a mediator of the inflam- 
matory effects of TPA, the consequences of TPA are so 
pleiotropic that it is difficult to believe that loss of any single 
gene, save that for protein kinase C, would diminish its 
effects. However, it must be noted that one additional pa- 
thology present in about 25% of mice that survived past 
8 weeks of age was suppurative peritonitis, a condition 
characterized by full-blown classical inflammation of the 
peritoneum and surrounding organs. There is no ready 
explanation for this condition. These findings could be in- 
terpreted to mean either that COX-2 is not important for 
inflammatory reactions or, alternatively, that COX-2 is es- 
sential for the prevention of infections before they become 
complex and life threatening. Another possibility is that 
COX-2 is important for resolution of inflammatory re- 
sponses and repair of damaged tissue and that the perito- 
nitis observed is a result of the failure of the repair process 
in Ptgs2-‘- mice. Regardless, these findings will probably 
be of major interest to developers of the new COX-2- 
selective NSAIDs. 
A number of questions remain about the function of 
COX-1 and COX-2 that can now be answered relatively 
quickly and easily with these transgenic animals. It will be 
important to examine how these animals survive infection 
and how they respond in more prolonged models of inflam- 
mation, particularly ones that more closely mimic human 
diseases such as rheumatoid arthritis. It will also be fasci- 
nating to examine how fever is regulated in the two homo- 
zygous strains and whether the pain response is modified 
in these mice. From experiments with the COX-2-selective 
inhibitors, one would predict that the Ptgs2-I- mice would 
be deficient in both regulation of fever and nociception. 
Finally, as discussed below, it will be interesting to deter- 
mine whether Pfgs2-‘- mice are resistant to experimentally 
induced colon cancer. 
Role of Prostaglandins in Colon Cancer? 
Case control and prospective studies have found a re- 
duced occurrence of colorectal cancer and lower mortality 
from the disease among frequent aspirin users. In a recent 
report by Biovannucci et al. (1995), long-term (over 20 
years) regular use of as few as four to six aspirin per week 
reduced the risk of colorectal cancer by almost half. To 
understand better the mechanism for the prophylactic ef- 
fect of aspirin, three research groups (Eberhart et al., 
1994; Kargman et al., 1995; Sano et al., 1995) have exam- 
ined COX-1 and COX-2 expression in normal and malig- 
nant colon tissues. Each of these studies arrived at the 
same major conclusions. COX-1 is expressed constitu- 
tively, and its levels are similar in normal and transformed 
colon tissue. COX-2 is not expressed in nontumor tissue, 
but is elevated in about 90% of colonic carcinomas. COX-2 
was also present in about 40% of less advanced adeno- 
mas, but infrequently in polyps. While these studies point 
an accusing finger toward COX-2, they provide no expla- 
nation for the protective mechanism of aspirin, nor for the 
role that COX-2 might play in the development of these 
cancers. From these initial studies, it is not obvious 
whether elevation of COX-2 is the cause or the result of 
malignant transformation. 
Tsujii and DuBois (1995) provide potential answers to 
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all of these questions. They have examined the effects 
that elevated COX-2 has on intestinal epithelia in vivo us- 
ing stably transfected epithelial cells expressing high lev- 
els of this enzyme. They demonstrate that when normal 
rat intestinal epithelial cells are plated onto extracellular 
matrices that mimic basement membranes, they rapidly 
undergo apoptosis. However, rat intestinal epithelial cells 
expressing high levels of COX-2 are refractive to apoptosis 
when plated on the same matrices. Importantly, the resis- 
tance to apoptosis in COX-Btransfected cells could be 
reversed bytheNSAlDsulindacsulfide(which, likeaspirin, 
inhibits both COX-1 and COX-2), one of only two reported 
instances in which NSAlDs have been shown to promote 
apoptosis. v-src-transformed chicken embryo fibroblasts 
also undergo programmed cell death when treated with 
NSAlDs (Lu et al., 1995). Other important properties of 
the COXZ-expressing epithelial cell lines were enhanced 
expression of Bc/2 and decreased expression of the trans- 
forming growth factor type II receptor, E-cadherin, and 
alkaline phosphatase. These are all phenotypic character- 
istics of immature apoptotic-resistant epithelial cells. Alka- 
line phosphatase expression could also be increased by 
COX inhibitors. 
These experiments by Tsujii and DuBois (1995) demon- 
strate that COX-2 can interfere with the normal differentia- 
tive processes of cultured intestinal epithelial cells. In vivo, 
intestinal epithelial cells usually mature and die within 4 
days. Elevated COX-2 levels in the early stages of epithe- 
lial transformation could possibly confer a nonapoptotic 
phenotype to epithelial cells in vivo. Thus, one potential 
mechanism for the prophylactic effects of aspirin and other 
NSAlDs would be to maintain the normal apoptotic poten- 
tial of colonic epithelial cells in the initial stages of the 
transformation process and thus inhibit the multistep pro- 
gression to carcinomas. 
Although the validity of this hypothesis will require fur- 
ther testing, it represents a cohesive explanation for 
NSAID actions in colon cancer and provides a plausible 
model to test. One potential problem with the model is 
that it predicts that elevated COX-2 levels should be im- 
portant in the initial steps leading to carcinoma formation, 
while elevated levels of COX-2 are consistently observed 
only after carcinoma formation. Of course, one could ar- 
gue that carcinomas are derived from single progenitor 
cells that express high levels of COX-2 and that such ex- 
pression is not observable until clonal expansion of such 
cells results in a tumor. Whether these findings are eventu- 
ally substantiated or not, the paper by Tsujii and DuBois 
(1995) should stimulate significant research that will has- 
ten our understanding of a serious human disease. 
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